StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a report released on Saturday. The brokerage issued a sell rating on the biotechnology company's stock.
A number of other research analysts also recently weighed in on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a research note on Friday, April 29th. Robert W. Baird dropped their price target on Genocea Biosciences from $8.00 to $3.00 in a research report on Monday, April 11th. Finally, HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a research report on Friday, April 29th.
Get Genocea Biosciences alerts:
Genocea Biosciences Price Performance
Shares of GNCA stock opened at $0.02 on Friday. The stock's 50 day simple moving average is $0.06 and its 200 day simple moving average is $0.62. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. Genocea Biosciences has a twelve month low of $0.01 and a twelve month high of $2.20. The company has a market capitalization of $910,377.00, a price-to-earnings ratio of -0.03 and a beta of 2.26.
Insider Transactions at Genocea Biosciences
In other news, Director Ali Behbahani sold 4,445,093 shares of Genocea Biosciences stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the sale, the insider now directly owns 4,445,093 shares in the company, valued at approximately $311,156.51. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,537,612 shares of company stock valued at $781,461. 1.61% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Genocea Biosciences
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC lifted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after acquiring an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. 59.25% of the stock is owned by institutional investors.
Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
See Also
Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
Is There Finally Green Ahead for These 2 Cannabis Leaders?
Ford Races Higher: Has The Stock Finally Bottomed?
A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
These Consumer Stocks Will Thrive And Here's Why
PayPal Stock is Attempting to Put in the Floor
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
斯托克新闻网在周六发布的一份报告中对Genocea Biosciences(纳斯达克:GNCA)的股票进行了报道。该经纪公司对这家生物技术公司的股票发布了卖出评级。
其他一些研究分析师最近也对GNCA发表了看法。Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的评级从买入下调至持有。罗伯特·W·贝尔德在4月11日星期一的一份研究报告中将他们对Genocea Biosciences的目标价从8.00美元下调至3.00美元。最后,在4月29日星期五的一份研究报告中,HC Wainwright将Genocea Biosciences的评级从买入下调至中性。
到达Genocea生物科学警报:
Genocea Bioscions价格表现
上周五,GNCA的股票开盘报0.02美元。该股的50日简单移动均线切入位为0.06美元,200日简单移动均线切入位为0.62美元。该公司的负债权益比率为0.24,速动比率为1.35,流动比率为1.35。Genocea Biosciences的12个月低点为0.01美元,12个月高位为2.20美元。该公司市值为910,377.00美元,市盈率为-0.03,贝塔系数为2.26。
Genocea Biosciences的内幕交易
其他消息,董事阿里巴巴-SW贝赫巴哈尼在5月25日(星期三)的一笔交易中出售了4445,093股基因生物科学公司的股票。该股以0.08美元的平均价格出售,总成交金额为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个超级链接获得。在相关新闻中,董事阿里巴巴-SW贝赫巴哈尼在5月25日(星期三)的一次交易中出售了4445,093股该公司的股票。这只股票的平均售价为0.08美元,总价值为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个链接访问。此外,大股东保罗·爱德华·沃克在5月24日星期二的一次交易中出售了5931,843股该公司的股票。这些股票的平均价格为0.07美元,总价值为415,229.01美元。出售完成后,该内部人士现在直接拥有该公司4,445,093股,价值约311,156.51美元。此次拍卖的披露信息可在此处找到。在上个季度,内部人士出售了10,537,612股公司股票,价值781,461美元。1.61%的股份由企业内部人士持有。
对冲基金参与Genocea Bioscions
一家机构投资者最近提高了对Genocea Biosciences股票的头寸。据Genocea Biosciences,Inc.(纳斯达克代码:GNCA-GET评级)在最近一次向美国证券交易委员会披露的信息中称,该公司第四季度将其在该公司股票的持仓量提高了49.4%。该基金在本季度增持了10,576股后,持有这家生物技术公司31,981股股票。在最近一次报告期结束时,Federal Equity Services LLC拥有Genocea Biosciences约0.06%的股份,价值3.7万美元。59.25%的股票由机构投资者持有。
Genocea Biosciences公司简介
(获取评级)
Genocea Biosciences,Inc.是一家生物制药公司,发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS,该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
另请参阅
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。